Drugs / PORT-77
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06346509 | Apr 2024 → Dec 2025 | — | Portal Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06971900 | Apr 2025 → Jan 2026 overdue | erythropoietic protoporphyria | Portal Therapeutics, Inc. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PORT-77 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06346509 ↗ |
| Route | Oral | “PORT-77 Administered Orally” NCT06346509 ↗ |